EEF2
Basic information
Region (hg38): 19:3976056-3985463
Previous symbols: [ "EF2" ]
Links
Phenotypes
GenCC
Source:
- spinocerebellar ataxia type 26 (Supportive), mode of inheritance: AD
- spinocerebellar ataxia type 26 (Strong), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Spinocerebellar ataxia 26 | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic | 15732118; 23001565 |
ClinVar
This is a list of variants' phenotypes submitted to
- not provided (1 variants)
- Spinocerebellar ataxia type 26 (1 variants)
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the EEF2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 91 | 37 | 135 | |||
missense | 122 | 124 | ||||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 4 | |||||
inframe indel | 2 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 9 | 19 | 3 | 31 | ||
non coding | 48 | 35 | 91 | |||
Total | 1 | 1 | 144 | 140 | 72 |
Variants in EEF2
This is a list of pathogenic ClinVar variants found in the EEF2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-3976255-G-A | Benign (Jun 20, 2021) | |||
19-3976323-T-G | Benign (Jun 09, 2021) | |||
19-3976443-G-A | Benign (May 11, 2021) | |||
19-3976551-C-T | not specified • EEF2-related disorder | Benign (May 04, 2021) | ||
19-3976601-G-A | not specified | Benign (Dec 11, 2023) | ||
19-3976610-G-A | Uncertain significance (May 11, 2022) | |||
19-3976623-C-T | not specified | Likely benign (Feb 16, 2022) | ||
19-3976624-G-A | Uncertain significance (Dec 06, 2022) | |||
19-3976635-G-A | EEF2-related disorder | Benign/Likely benign (May 30, 2023) | ||
19-3976648-C-T | not specified | Uncertain significance (Mar 01, 2024) | ||
19-3976652-T-C | not specified | Uncertain significance (Mar 01, 2024) | ||
19-3976656-G-T | Uncertain significance (Sep 28, 2022) | |||
19-3976668-G-A | not specified • EEF2-related disorder | Likely benign (Dec 14, 2016) | ||
19-3976671-C-A | not specified | Likely benign (Jun 22, 2023) | ||
19-3976671-C-G | not specified | Benign (Jan 21, 2024) | ||
19-3976682-A-C | Uncertain significance (Jun 02, 2021) | |||
19-3976690-A-C | Uncertain significance (Feb 13, 2023) | |||
19-3976699-T-C | Uncertain significance (Nov 30, 2022) | |||
19-3976701-G-A | not specified | Benign (Jul 29, 2023) | ||
19-3976707-C-T | not specified • EEF2-related disorder | Benign (Jan 22, 2024) | ||
19-3976708-G-A | not specified | Uncertain significance (Jan 10, 2022) | ||
19-3976716-G-A | not specified | Benign/Likely benign (Sep 05, 2023) | ||
19-3976741-G-A | Uncertain significance (Dec 31, 2023) | |||
19-3976750-G-A | Likely benign (Apr 24, 2023) | |||
19-3976756-G-A | Uncertain significance (May 08, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
EEF2 | protein_coding | protein_coding | ENST00000309311 | 15 | 9414 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.00 | 0.0000534 | 125639 | 0 | 2 | 125641 | 0.00000796 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 4.88 | 235 | 560 | 0.420 | 0.0000368 | 5597 |
Missense in Polyphen | 61 | 255.81 | 0.23845 | 2502 | ||
Synonymous | -6.67 | 387 | 252 | 1.53 | 0.0000198 | 1664 |
Loss of Function | 5.31 | 2 | 36.7 | 0.0545 | 0.00000182 | 417 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.00000883 | 0.00000880 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000327 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Catalyzes the GTP-dependent ribosomal translocation step during translation elongation. During this step, the ribosome changes from the pre-translocational (PRE) to the post- translocational (POST) state as the newly formed A-site-bound peptidyl-tRNA and P-site-bound deacylated tRNA move to the P and E sites, respectively. Catalyzes the coordinated movement of the two tRNA molecules, the mRNA and conformational changes in the ribosome.;
- Disease
- DISEASE: Spinocerebellar ataxia 26 (SCA26) [MIM:609306]: A form of spinocerebellar ataxia, a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to degeneration of the cerebellum with variable involvement of the brainstem and spinal cord. {ECO:0000269|PubMed:23001565}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Oxytocin signaling pathway - Homo sapiens (human);AMPK signaling pathway - Homo sapiens (human);Translation Factors;AMP-activated Protein Kinase (AMPK) Signaling;Brain-Derived Neurotrophic Factor (BDNF) signaling pathway;Neutrophil degranulation;Disease;Uptake and function of diphtheria toxin;Translation;Post-translational protein modification;Metabolism of proteins;Uptake and actions of bacterial toxins;Synthesis of diphthamide-EEF2;Gamma carboxylation, hypusine formation and arylsulfatase activation;Infectious disease;Innate Immune System;Immune System;Protein methylation;Peptide chain elongation;Eukaryotic Translation Elongation;mTOR signaling pathway
(Consensus)
Recessive Scores
- pRec
- 0.506
Intolerance Scores
- loftool
- 0.101
- rvis_EVS
- -2.28
- rvis_percentile_EVS
- 1.24
Haploinsufficiency Scores
- pHI
- 0.936
- hipred
- Y
- hipred_score
- 0.783
- ghis
- 0.590
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.963
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Eef2
- Phenotype
- embryo phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); growth/size/body region phenotype; cellular phenotype;
Gene ontology
- Biological process
- hematopoietic progenitor cell differentiation;response to ischemia;skeletal muscle contraction;translational elongation;aging;glial cell proliferation;response to estradiol;response to endoplasmic reticulum stress;skeletal muscle cell differentiation;response to hydrogen peroxide;neutrophil degranulation;response to ethanol;positive regulation of translation;response to folic acid;cellular response to brain-derived neurotrophic factor stimulus;positive regulation of cytoplasmic translation
- Cellular component
- extracellular region;nucleus;cytoplasm;cytosol;plasma membrane;membrane;aggresome;secretory granule lumen;polysomal ribosome;membrane raft;synapse;extracellular exosome;ficolin-1-rich granule lumen;ribonucleoprotein complex
- Molecular function
- p53 binding;RNA binding;translation elongation factor activity;GTPase activity;protein binding;GTP binding;5S rRNA binding;protein kinase binding;ribosome binding;cadherin binding;actin filament binding